Brousil Philip, Shabbir Majid, Zacharakis E, Sahai Arun
Department of Urology, Guy's and St Thomas' NHS Trust, King's Health Partners, London, UK.
Curr Drug Targets. 2015;16(11):1180-6. doi: 10.2174/138945011611151013164756.
Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS) are a highly prevalent problem, and with considerable burden to quality of life. Evidence has emerged that a strong correlation exists in men suffering both BPH-LUTS and erectile dysfunction (ED). Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to be highly effective in treating ED and more recently there is evidence that men with LUTS also benefit. In this review article we discuss the common pathogenic pathways of ED and LUTS, the scientific basis of PDE5i use, the efficacy of PDE5i in LUTS either as monotherapy or in combination with other established medications used in LUTS.
与良性前列腺增生相关的下尿路症状（BPH-LUTS）是一个非常普遍的问题，给生活质量带来相当大的负担。有证据表明，同时患有BPH-LUTS和勃起功能障碍（ED）的男性之间存在很强的相关性。5型磷酸二酯酶抑制剂（PDE5i）已被证明在治疗ED方面非常有效，最近有证据表明，患有LUTS的男性也能从中受益。在这篇综述文章中，我们讨论了ED和LUTS的常见致病途径、使用PDE5i的科学依据、PDE5i作为单一疗法或与LUTS中使用的其他既定药物联合使用时对LUTS的疗效。
